Sugi Predict

Sugi Predict / Compounds / SCHEMBL5708384

SCHEMBL5708384

SCHEMBL5708384

CC(C)(C)OC(=O)NCC(O)CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.42
▸ SLC22A6 Q4U2R8 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CTSS P25774 4/20 0.40
▸ CTSK P43235 4/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ SERPINE1 P05121 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ MAOA P21397 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ GABRR1 P24046 2/20 0.36
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765616 1.00 MEN1 (0.47) MEN1GAAKMT2ATDP1SLC22A6
SCHEMBL5708383 1.00 MEN1 (0.47) MEN1GAAKMT2ATDP1SLC22A6
SCHEMBL28097950 0.98 MEN1 (0.46) MEN1GAAKMT2ATDP1SLC22A6
SCHEMBL570033 0.87 MEN1 (0.50) MEN1GAAKMT2ATDP1SYK
SCHEMBL23949295 0.84 MAOA (0.46) MEN1GAAKMT2ATDP1SYK
SCHEMBL15297382 0.84 CYP2D6 (0.43) MEN1GAAKMT2ATDP1SYK
SCHEMBL15570371 0.84 CYP2D6 (0.43) MEN1GAAKMT2ATDP1SYK
SCHEMBL13906658 0.84 MEN1 (0.49) MEN1GAAKMT2ATDP1SYK
SCHEMBL31072227 0.84 MEN1 (0.49) MEN1GAAKMT2ATDP1SYK
SCHEMBL12475162 0.84 MEN1 (0.49) MEN1GAAKMT2ATDP1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528781-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-01-20 — — US disclosed
EP-4192831-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 — — EP disclosed
US-20240376061-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-11-14 — — US disclosed
US-11897851-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2024-02-13 — — US disclosed
CN-116323599-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-06-23 — — CN disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 — — US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 — — US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 — — US disclosed
EP-4192831-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-06-14 — — EP disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 — — US disclosed
WO-2012142457-A2 MACROLACTAM COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA THE BROAD INSTITUTE, INC. (US) 2012-10-18 — — WO disclosed
EP-1008590-B1 Process for preparing optically active oxazolidinone derivatives TAKASAGO PERFUMERY CO LTD (JP) 2006-10-11 — — EP disclosed
EP-1091943-B1 NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES PFIZER PROD INC (US) 2005-11-30 — — EP disclosed
US-6403804-B1 ALLOWING HYDRAZINE TO REACT ON OPTICALLY ACTIVE ACID ESTER HAVING HYDROXYL GROUP AT 3-POSITION TO GIVE OPTICALLY ACTIVE HYDRAZIDE HAVING HYDROXYL GROUP AT 3-POSITION, SUBJECTING OPTICALLY ACTIVE HYDRAZIDE TO CURTIUS REARRANGEMENT TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-06-11 — — US disclosed
US-6355662-B1 PEPTIDE AND NONPEPTIDES AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS PFIZER INC 2002-03-12 — — US disclosed
US-6306887-B1 AROMATIC UREAS, CARBAMATES AND TRIAMINONITRILES AND HETEROCYCLIC COMPOUNDS PFIZER INC 2001-10-23 — — US disclosed
EP-1091943-A1 NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES Pfizer Products Inc. (US) 2001-04-18 — — EP disclosed
EP-1008590-A1 Process for preparing optically active oxazolidinone derivative Takasago International Corporation (JP) 2000-06-14 — — EP disclosed
WO-2000000477-A1 NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES PFIZER PRODUCTS INC. (US) 2000-01-06 — — WO disclosed
US-4992544-A Intermediates for b-lactam antibiotics and b-lactamase inhibitor UNIVERSITY OF NOTRE DAME DU LAC (US) 1991-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MEN1 418/4885GAA 1010/4885KMT2A 4112/4885
US-11897851-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR MEN1 418/4885GAA 1010/4885KMT2A 4112/4885
US-12528781-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, VIP MEN1 1749/4885GAA 1396/4885KMT2A 3022/4885
US-20240376061-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MEN1 418/4885GAA 1010/4885KMT2A 4112/4885
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL MEN1 896/4885GAA 1601/4885KMT2A 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.